Cardiff Oncology, Inc.(CRDF)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRDF Cardiff Oncology, Inc.

休市中 08-14 16:00:00 EDT

0.9630

-0.0210

-2.13%

盘后1.01

+0.0420+4.36%

19:48 EDT

最高1.02	最低0.9600	成交量48.13万
今开0.9768	昨收0.9840	日振幅6.10%
总市值7,480万	流通市值7,245万	总股本7,767万
成交额47.16万	换手率0.64%	流通股本7,524万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":0.963,"timestamp":1786737600000,"preClose":0.984,"halted":0,"volume":481303,"hourTrading":{"tag":"盘后","latestPrice":1.005,"preClose":0.963,"latestTime":"19:48 EDT","volume":20287,"amount":19189.2287,"timestamp":1786751307947,"change":0.042,"changeRate":0.043614,"amplitude":0.077882},"delay":0,"changeRate":-0.021341463414634165,"floatShares":75235000,"shares":77673000,"eps":-0.595681,"marketStatus":"休市中","change":-0.021,"latestTime":"08-14 16:00:00 EDT","open":0.9768,"high":1.02,"low":0.96,"amount":471603.36321039003,"amplitude":0.060976,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.595681,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":0.984,"preHourTrading":{"tag":"盘前","latestPrice":0.9758,"preClose":0.984,"latestTime":"09:08 EDT","volume":542,"amount":531.6689921999999,"timestamp":1786712919150,"change":-0.0082,"changeRate":-0.008333,"amplitude":0.04878},"postHourTrading":{"tag":"盘后","latestPrice":1.005,"preClose":0.963,"latestTime":"19:48 EDT","volume":20287,"amount":19189.2287,"timestamp":1786751307947,"change":0.042,"changeRate":0.043614,"amplitude":0.077882},"volumeRatio":0.5481863379577059,"impliedVol":1.8975,"impliedVolPercentile":0.7928},"requestUrl":"/m/hq/s/CRDF/wiki","defaultTab":"wiki","newsList":[{"id":"1130468100","title":"Cardiff Oncology：30毫克Onvansertib联合FOLFIRI/贝伐珠单抗方案客观缓解率达72.2%，显著优于标准疗法的42.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130468100","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130468100?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:12","pubTimestamp":1780405945,"startTime":"0","endTime":"0","summary":"Cardiff Oncology公司公布的最新临床数据显示，其30毫克剂量Onvansertib联合FOLFIRI化疗方案与贝伐珠单抗的治疗组，取得了高达72.2%的客观缓解率。这一结果与标准治疗组42.1%的客观缓解率形成了鲜明对比，展现出显著的疗效优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182558584","title":"Cardiff Oncology公布Onvansertib一线治疗Ras突变转移性结直肠癌的随机对照二期试验积极数据，将于2026年ASCO年会上展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1182558584","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182558584?lang=zh_cn&edition=full","pubTime":"2026-06-02 21:11","pubTimestamp":1780405875,"startTime":"0","endTime":"0","summary":"Cardiff Oncology宣布，其Onvansertib用于一线治疗Ras突变转移性结直肠癌的随机对照二期临床试验取得积极结果，相关数据将在2026年美国临床肿瘤学会年会上进行展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151982459","title":"Cardiff Oncology, Inc. 寻求针对 Nms 的禁令救济与确认判决 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1151982459","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151982459?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:03","pubTimestamp":1779224612,"startTime":"0","endTime":"0","summary":"Cardiff Oncology, Inc. 已通过提交给美国证券交易委员会的文件披露，该公司正针对Nms提起诉讼，寻求法院的禁令救济以及一项确认判决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182918615","title":"Cardiff Oncology, Inc. 就Onvansertib许可协议违约对Nerviano Medical Sciences提起诉讼 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1182918615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182918615?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:03","pubTimestamp":1779224604,"startTime":"0","endTime":"0","summary":"Cardiff Oncology, Inc.  已向美国证券交易委员会提交文件，披露其已对Nerviano Medical Sciences提起诉讼，指控后者违反了关于在研药物Onvansertib的许可协议。根据提交的SEC文件，Cardiff Oncology指控Nerviano Medical Sciences未能履行其在许可协议项下的义务，构成了违约行为。此次诉讼的核心争议点围绕Onvansertib的相关权利与责任展开。该法律行动标志着双方在Onvansertib开发合作上出现了重大分歧。Cardiff Oncology通过此举旨在寻求法律救济，以维护其基于该许可协议所享有的权益。事件的发展可能对Onvansertib未来的研发与商业化进程产生影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127493618","title":"Cardiff Oncology任命Josh Muntner为首席财务官、Ajay Aggarwal为首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=1127493618","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127493618?lang=zh_cn&edition=full","pubTime":"2026-04-10 04:02","pubTimestamp":1775764943,"startTime":"0","endTime":"0","summary":"Cardiff Oncology, Inc.宣布两项重要人事任命：Josh Muntner将于4月6日起担任公司首席财务官，而Ajay Aggarwal则自4月27日起出任首席运营官。\n此次高层人事变动将进一步加强公司管理团队实力，为后续战略发展提供重要支撑。两位高管在生物制药领域均拥有丰富的财务管理及运营经验，他们的加入有望推动公司在肿瘤治疗领域的研发与商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614011420","title":"Cardiff Oncology, Inc.盘中异动 股价大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614011420","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614011420?lang=zh_cn&edition=full","pubTime":"2026-02-27 00:16","pubTimestamp":1772122584,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日00时16分，Cardiff Oncology, Inc.股票出现异动，股价大幅拉升5.18%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为2.33%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227001624a4cc36e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227001624a4cc36e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614913620","title":"Cardiff Oncology, Inc.盘中异动 早盘大幅上涨6.47%报1.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614913620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614913620?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:34","pubTimestamp":1772030062,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日22时34分，Cardiff Oncology, Inc.股票出现波动，股价快速上涨6.47%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225223422a4c7a954&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225223422a4c7a954&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518847203","title":"Cardiff Oncology, Inc.盘中异动 下午盘快速下挫5.19%报3.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518847203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518847203?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:11","pubTimestamp":1741626690,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时11分，Cardiff Oncology, Inc.股票出现波动，股价快速跳水5.19%。截至发稿，该股报3.66美元/股，成交量38.3547万股，换手率0.58%，振幅5.19%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311011130a26a766f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311011130a26a766f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517452649","title":"Cardiff Oncology, Inc.2024财年实现净利润-45.43百万美元，同比减少9.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517452649","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517452649?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363258,"startTime":"0","endTime":"0","summary":"3月8日，Cardiff Oncology, Inc.公布财报，公告显示公司2024财年净利润为-45.43百万美元，同比减少9.63%；其中营业收入为683000.00美元，同比增加39.96%，每股基本收益为-0.95美元。从资产负债表来看，Cardiff Oncology, Inc.总负债14.24百万美元，其中短期债务710000.00美元，资产负债比为6.83，流动比率为7.08。机构评级：截至2025年3月8日，当前有4家机构对Cardiff Oncology, Inc.目标价做出预测，其中目标均价为14.25美元，其中最低目标价为10.00美元，最高目标价为20.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000249a2647fc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000249a2647fc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517161846","title":"Cardiff Oncology, Inc.盘中异动 早盘大幅下挫5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517161846?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:35","pubTimestamp":1741271739,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时35分，Cardiff Oncology, Inc.股票出现异动，股价急速下挫5.15%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223539963c4db0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223539963c4db0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517946697","title":"Cardiff Oncology, Inc.盘中异动 急速上涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517946697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517946697?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:32","pubTimestamp":1741188766,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时32分，Cardiff Oncology, Inc.股票出现异动，股价急速拉升5.09%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.20%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233246abe9c451&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233246abe9c451&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516559796","title":"Cardiff Oncology, Inc.盘中异动 快速下挫5.07%报4.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516559796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516559796?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:12","pubTimestamp":1741018338,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时12分，Cardiff Oncology, Inc.股票出现波动，股价大幅跳水5.07%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为3454.38%、151.02%、139.72%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Radiopharm Theranostics Limited，振幅分别为206.20%、70.53%、53.50%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304001219abe65461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304001219abe65461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320288","title":"Cardiff Oncology, Inc.盘中异动 大幅上涨5.30%报4.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320288?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:35","pubTimestamp":1740753340,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时35分，Cardiff Oncology, Inc.股票出现异动，股价急速上涨5.30%。截至发稿，该股报4.28美元/股，成交量15.4379万股，换手率0.23%，振幅3.75%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223540abe0ebfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223540abe0ebfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118930078","title":"Cardiff Oncology第四季度GAAP每股收益$(0.21)优于预期$(0.24)，销售额$151.00K优于预期$94.17K","url":"https://stock-news.laohu8.com/highlight/detail?id=1118930078","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118930078?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:38","pubTimestamp":1740692305,"startTime":"0","endTime":"0","summary":"Cardiff Oncology报告季度每股亏损$，优于分析师一致预期的$，增长了12.5%。与去年同期的销售额$156.00千相比下降了3.21%。以上内容来自Benzinga Earnings专栏，原文如下：Cardiff Oncology  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 12.5 percent. This is unchanged from the same period last year.  The company reported quarterly sales of $151.00 thousand which beat the analyst consensus estimate of $94.17 thousand by 60.35 percent.  This is a 3.21 percent decrease over sales of $156.00 thousand the same period last","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cardiff Oncology第四季度GAAP每股收益$(0.21)优于预期$(0.24)，销售额$151.00K优于预期$94.17K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514163386","title":"Cardiff Oncology, Inc.盘中异动 早盘股价大跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514163386","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514163386?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:57","pubTimestamp":1740668275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时57分，Cardiff Oncology, Inc.股票出现波动，股价快速下跌5.16%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227225755989515c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227225755989515c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514517328","title":"Cardiff Oncology, Inc.盘中异动 快速上涨5.20%报4.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514517328","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514517328?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:12","pubTimestamp":1740582765,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时12分，Cardiff Oncology, Inc.股票出现异动，股价快速上涨5.20%。截至发稿，该股报4.45美元/股，成交量10.325万股，换手率0.16%，振幅4.96%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226231245963157ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226231245963157ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513262290","title":"Cardiff Oncology, Inc.盘中异动 大幅拉升5.11%报4.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513262290","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513262290?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:00","pubTimestamp":1740157242,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时00分，Cardiff Oncology, Inc.股票出现异动，股价急速拉升5.11%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Invivyd, Inc.、Osr Holdings, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为235.52%、182.05%、124.79%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为72.46%、57.50%、48.35%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222010043a24ed09c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222010043a24ed09c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512516486","title":"Cardiff Oncology, Inc.盘中异动 早盘股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512516486","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512516486?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:23","pubTimestamp":1739978612,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时23分，Cardiff Oncology, Inc.股票出现异动，股价大幅拉升5.19%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 、Immunitybio, Inc.涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为432.79%、233.59%、146.58%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.、Allogene Therapeutics, Inc.，振幅分别为207.68%、159.49%、36.97%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219232332a24c062e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219232332a24c062e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512165535","title":"Cardiff Oncology, Inc.盘中异动 快速拉升5.94%报4.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512165535?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:35","pubTimestamp":1739889302,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时35分，Cardiff Oncology, Inc.股票出现异动，股价大幅拉升5.94%。截至发稿，该股报4.55美元/股，成交量4.606万股，换手率0.07%，振幅2.11%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223502abd3affe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223502abd3affe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511757251","title":"Cardiff Oncology, Inc.盘中异动 股价大跌5.18%报4.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511757251","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511757251?lang=zh_cn&edition=full","pubTime":"2025-02-14 04:03","pubTimestamp":1739477008,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日04时03分，Cardiff Oncology, Inc.股票出现异动，股价急速下跌5.18%。截至发稿，该股报4.12美元/股，成交量51.3894万股，换手率0.77%，振幅5.99%。Cardiff Oncology, Inc.股票所在的生物技术行业中，整体涨幅为1.06%。Cardiff Oncology, Inc.公司简介：Cardiff Oncology Inc是一家临床阶段的生物技术公司，利用PLK1抑制开发针对一系列癌症的新疗法，以满足最大的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021404032898846c13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021404032898846c13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":-0.0291},{"period":"1month","weight":0.0829},{"period":"3month","weight":-0.4234},{"period":"6month","weight":-0.3981},{"period":"1year","weight":-0.6053},{"period":"ytd","weight":-0.6573}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cardiff Oncology, Inc.于2002年4月26日在佛罗里达州注册成立。该公司是一家临床阶段的生物技术公司，利用PLK1抑制（一种经过充分验证的肿瘤药物靶点）开发跨越一系列未满足医疗需求的癌症的新疗法。该公司的目标是通过onvansertib、公司口服和高选择性PLK1抑制剂以及标准护理疗法的治疗组合来针对肿瘤脆弱性。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.023989},{"month":2,"riseRate":0.5,"avgChangeRate":0.28397},{"month":3,"riseRate":0.357143,"avgChangeRate":0.075052},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.062128},{"month":5,"riseRate":0.5,"avgChangeRate":0.055529},{"month":6,"riseRate":0.357143,"avgChangeRate":0.244554},{"month":7,"riseRate":0.4,"avgChangeRate":-0.096823},{"month":8,"riseRate":0.6,"avgChangeRate":0.102496},{"month":9,"riseRate":0.285714,"avgChangeRate":0.016213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.01141}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cardiff Oncology, Inc.(CRDF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cardiff Oncology, Inc.(CRDF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}